ABO BLOOD GROUP TYPE AND RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH LYMPHOMA

Introduction: Risk of venous thromboembolism (VTE) is increased in patients with cancer owing to various pathophysiological mechanisms that generate prothrombotic state. Lymphoma are well known be at significant risk for VTE development. Recently, non-O blood type was associated and it has been proposed as time-dependent predictor group patients. The aim the study examine ABO a factor development lymphoma. Methods: A total 600 lymphoma (newly diagnosed relapsed) have included study. All treated Center, Clinic Hematology, University Clinical Center Serbia. Data regarding events collected all study, from time diagnosis 3 months after last cycle therapy. determined prior treatment initialization through standard institutional procedure. objectively based on radiographic studies, clinical examination, laboratory evaluation. Results: median patients' age 57 years (range 18–89 years); 55.5% were males. majority newly (88.8%). distribution following: indolent NHL 140 (23.3%), aggressive 366 (61%), Hodgkin 94 (15.7%), respectively. rate 10.3% (62 patients), highest (7.7%, 46 patients). before specific hematological initiation 46.8% patients, whilst 53.2% commencement. most common our (41.6%), followed by O (33.3%), B (15.8%) AB (9.3%), There no statistically association between (p = 0.495). Non-O had significantly more often developed comparison (2.5% vs. 1%, p 0.04), whereas (3.8% 3%, 0.04). Logistic regression model demonstrated pre-treatment (odds ratio [OR] 3.19, confidence interval [CI]: 1.03–9.88, 0.044). Conclusions: While there frequency shown hematologic Encore Abstract—previously submitted EHA 2023 Keywords: diagnostic prognostic biomarkers, Lymphoid Cancers - Other No conflicts interests pertinent abstract.